Supplement Quality & FDA Leadership | Key Industry Updates

Gummy Vitamin Quality Concerns

Independent testing of 25 vitamin C gummy products sold on Amazon revealed significant gaps in label accuracy. The analysis, conducted by U.S. manufacturer NOW, found that 12 of the tested products contained almost no detectable vitamin C. Only 13 of the 25 items met the claims stated on their packaging. Some samples marketed as 1,000 mg supplements contained less than 2 mg per gummy. Dan Richard, the vice president of global sales and marketing at NOW, described the findings as deeply disappointing. The company has conducted these marketplace tests for nine years, yet they report little improvement in industry standards for these specific products.

NOW claims they shared these findings with Amazon and the FDA. To date, the company reports no significant action from these organizations to address the presence of substandard items on the platform. The discrepancy highlights ongoing problems with dishonest marketing and inconsistent testing methods within the supplement sector. These results indicate a wider issue regarding consumer protection for popular chewable vitamins.

GNC Expansion into Singapore

Retailer GNC is shifting its distribution strategy in Singapore to restore its presence in the market. The Pittsburgh-based company is re-establishing standalone stores while building a retail footprint through a partnership with Guardian. GNC entered an exclusive distribution agreement with DFI Retail Group, the parent company of the Guardian chain, to facilitate this move.

Standalone stores provide a specialized environment for consumers to access a broader range of GNC products. The partnership with Guardian offers increased accessibility through a larger network. According to a DFI spokesperson, the combination of these formats serves both the casual shopper and the dedicated customer seeking specific supplements. Products including vitamins, minerals, and sport nutrition items will be available in both formats by the fourth quarter of 2026.

Nomination for FDA Leadership

Dr. Heidi Overton is the latest nominee for FDA commissioner, appointed by President Trump. Her confirmation remains pending in the Senate. Overton currently works as a medical director and formerly served as chief policy officer at the America First Policy Institute. Industry leaders are watching the nomination closely as she is a new figure in the context of supplement regulation.

Stakeholders observe that Overton brings a focus on scientific principles and a cautious approach to unapproved peptide injections. Her background includes oversight of CBD policy at the White House Domestic Policy Council. The American Herbal Products Association (AHPA) stated that they support her nomination. Graham Rigby, president and CEO of the AHPA, noted her commitment to a pro-innovation posture and her use of industry resources when developing policy. Her previous work on hemp and CBD standards suggests a background that aligns with patient access to health-promoting products. The industry expects to gain more clarity on her specific regulatory agenda as the confirmation process continues.